CYBN - Helus Pharma Inc.

8.28
0.100   1.208%

Share volume: 717,701
Last Updated: 01-02-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.26%

PREVIOUS CLOSE
CHG
CHG%
$8.18
0.10
0.01%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
0%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 0%
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
40.10%
6 Months
32.06%
1 Year
13.58%
2 Year
2,148.78%
Key data
Stock price
$8.28
P/E Ratio 
0.00
DAY RANGE
$8.14 - $8.38
EPS 
N/A
52 WEEK RANGE
$4.81 - $9.83
52 WEEK CHANGE
$12.96
MARKET CAP 
193.722 M
YIELD 
N/A
SHARES OUTSTANDING 
759.692 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
06-25-2025
BETA 
1.17
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
N/A
AVERAGE 30 VOLUME 
N/A
Company detail
CEO: Douglas L. Drysdale
Region: US
Website: cybin.com
Employees: 50
IPO year: 2026
Issue type: Common Stock
Market: NYSE American
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders. It has also developed EMBARK, a psychedelic-assisted psychotherapy.

Recent news